Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 9, 2024Neurology

Characteristics of Patients Receiving Co-prescriptions for a Calcitonin Gene-related Peptide Monoclonal Antibody and a Gepant: A Retrospective, Observational Study (P8-12.003)

View Full Paper
Ask AI
Bookmark
Share

Authors

ANArathi NandyalaAGAnna Graber‐NaidichNZNiushen Zhang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Nandyala et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdadb6db643587677e87https://doi.org/10.1212/wnl.0000000000206061
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Analysis of Calcitonin Gene-Related Peptide Receptor Monoclonal Antibody and Antagonist Usage and Medication Switch Profile from a Tertiary Care Facility (P5-12.009)2024
  2. 2CGRP Monoclonal Antibodies vs Gepants: Risk of Vascular Outcomes: A TriNetX Multicenter Electronic Medical Record Analysis (P10-15.012)2026
  3. 3Utilization, Expenditure, and Treatment Patterns Associated With Calcitonin Gene-Related Peptide Monoclonal Antibodies Reimbursed Subject to a Managed Access Protocol in Ireland2024 · 3 citations
  4. 4Comparative Efficacy and Safety of CGRP Monoclonal Antibodies and Oral Gepants for Migraine Prevention: Evidence from Randomized Controlled Trials and Network Meta-analysis (P10-15.014)2026
  5. 5Optimizing Migraine Therapy: A Comparative Review of Dosage and Tolerability of Calcitonin Gene Related Peptide Antagonists2025